Evidence map›Paper›PMID 41073857›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Multiplex Digital PCR Assay Targeting DNA Methylation for Early Detection of Cancer.

Victoria Cannon, Jocelyn H Wright, Cecilia C S Yeung, William M Grady, Ming Yu

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Integrative systems biology analysis reveals diagnostic and prognostic DNA methylation signatures in esophageal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victoria CannonTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jocelyn H WrightTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Cecilia C S YeungTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
William M GradyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ming YuTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. myu@fredhutch.org.

Funding

Case Comprehensive Cancer Center NCTN Lead Academic Participating SiteUG1CA233234 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Aaron Thomas Gerds, Daniel Eidelberg Spratt · 2019 to 2026
$11.1M
Understanding adenoma progression: Interplay among tissue microenvironment, clonal architecture, and gut microbiomeU54CA274374 · NCI · FRED HUTCHINSON CANCER CENTER · PI William Mallory Grady · 2022 to 2026
$10.7M
Identify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7M
Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagusU2CCA271902 · NCI · FRED HUTCHINSON CANCER CENTER · PI William Mallory Grady · 2022 to 2026
$5.3M
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.R01CA220004 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, HALBERG, RICHARD BROTT · 2017 to 2021
$3.2M
The role of the senescent microenvironment on cancer initiating cells in the colon.U01AG077920 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY · 2021 to 2025
$2.6M
Translational Science of Gastrointestinal Cancer Initiation and ProgressionR50CA233042 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Ming Yu · 2018 to 2026
$2.4M
NCI NIH HHS R01 CA220004NCI NIH HHS R50 CA233042NCI NIH HHS U01 CA152756NCI NIH HHS U2C CA271902NCI NIH HHS U54 CA274374NCI NIH HHS UG1 CA233234NIA NIH HHS U01 AG077920
6 · The paper itself

Abstract

Digital PCR has been demonstrated to enable the precise nucleic acid absolute quantification across a wide range of applications. Historically, dPCR technology was limited to two channels for fluorescence detection. Recent advances in digital PCR have made it possible to multiplex and allow for simultaneous analysis of multiple targets within a PCR reaction. Here, we describe a multiplex dPCR assay for the detection and quantification of methylated DNA (also known as DNA-methylation-specific multiplex digital PCR, or DNA-methylation specific dPCR). We also demonstrate the application of this technology for the development of a candidate DNA methylation-based biomarker panel for the early detection of high-grade dysplasia and esophageal adenocarcinoma. Further, we discuss common technical challenges and troubleshooting for performing successful DNA-methylation-specific MS-dPCR assays.

Indexed as

AdenocarcinomaDNA MethylationEarly Detection of CancerEsophageal NeoplasmsMultiplex Polymerase Chain ReactionBiomarkers, TumorHumansBiomarkers, TumorBiomarkersDNA methylationEarly detection of cancerEsophageal adenocarcinomaMultiplex digital-PCR

Identifiers

PMID41073857
PMCPMC13436331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.